Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biogen Inc. (BIIB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. As a Nasdaq-listed biotechnology company, Biogen uses these filings to report financial results, material events and governance matters that are important for investors evaluating its activities in neurology, rare diseases and immunology.
Recent Form 8-K filings show how Biogen communicates results of operations and financial condition, including quarterly earnings press releases and preliminary estimates of acquired in-process research and development, upfront and milestone expenses. The company explains that these expenses arise from collaboration and license agreements and are presented as a separate line item in its condensed consolidated statements of income. Other 8-K filings cover shareholder votes at the annual meeting, such as the election of directors and ratification of the independent registered public accounting firm.
Through this page, users can review Biogen’s SEC-reported information alongside Stock Titan’s AI-powered tools, which can help summarize lengthy filings and highlight key items such as collaboration-related charges, capital allocation decisions and governance outcomes. Investors interested in Biogen’s partnerships, pipeline investments and financial reporting practices can use these filings to understand how the company accounts for its research collaborations, including those involving antisense oligonucleotides, monoclonal antibodies and emerging modalities.
In addition to 8-Ks, this page can link to other Biogen filings available on EDGAR, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company provides more detailed discussion of its business, risk factors and financial statements. Together, these documents form the regulatory record that underpins fundamental analysis of BIIB.
Biogen Inc. launches a tender offer to acquire Apellis Pharmaceuticals for $41.00 per share plus a contingent value right. Purchaser Aspen Purchaser Sub, a Biogen subsidiary, offers $41.00 in cash per Apellis share and one non-transferable contingent value right per share for up to an aggregate $4.00 upon specified milestones under a Contingent Value Rights Agreement, each subject to the terms of the Offer to Purchase. Apellis had 128,007,815 shares outstanding as of April 9, 2026, with additional potential dilution from convertible notes of $93,897,000 (convertible at 25.3405 shares per $1,000) and awarded equity awards described in the filing. The offer and the Merger Agreement govern the transaction; the Offer to Purchase, Letter of Transmittal, and merger documents are incorporated by reference.
Biogen Inc. launches a tender offer to acquire Apellis Pharmaceuticals for $41.00 per share plus a contingent value right. Purchaser Aspen Purchaser Sub, a Biogen subsidiary, offers $41.00 in cash per Apellis share and one non-transferable contingent value right per share for up to an aggregate $4.00 upon specified milestones under a Contingent Value Rights Agreement, each subject to the terms of the Offer to Purchase. Apellis had 128,007,815 shares outstanding as of April 9, 2026, with additional potential dilution from convertible notes of $93,897,000 (convertible at 25.3405 shares per $1,000) and awarded equity awards described in the filing. The offer and the Merger Agreement govern the transaction; the Offer to Purchase, Letter of Transmittal, and merger documents are incorporated by reference.
Biogen Inc., through its wholly owned subsidiary Aspen Purchaser Sub, Inc., provided pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals, Inc. pursuant to the Agreement and Plan of Merger dated March 31, 2026.
The communication states the tender offer has not commenced and that formal offer materials will be filed on Schedule TO at commencement; it urges Apellis securityholders to review the eventual offer documents and the solicitation/recommendation statement on Schedule 14D-9.
Biogen Inc., through its wholly owned subsidiary Aspen Purchaser Sub, Inc., provided pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals, Inc. pursuant to the Agreement and Plan of Merger dated March 31, 2026.
The communication states the tender offer has not commenced and that formal offer materials will be filed on Schedule TO at commencement; it urges Apellis securityholders to review the eventual offer documents and the solicitation/recommendation statement on Schedule 14D-9.
Biogen Inc. disclosed that its first-quarter 2026 results will include approximately $34 million in acquired in-process research and development, upfront and milestone expense on a pre-tax basis. This charge is expected to reduce GAAP and non-GAAP net income by about $0.19 per diluted share for the quarter ended March 31, 2026.
These expenses relate to collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of in-process R&D. Biogen noted that quarterly results are preliminary and subject to closing procedures, and actual results may differ from current estimates.
Biogen’s subsidiary announced pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals under an Agreement and Plan of Merger dated March 31, 2026. The communication states the tender offer has not yet commenced and that formal offer materials will be filed on Schedule TO when the offer begins. It directs Apellis securityholders to read the forthcoming offer documents and the solicitation/recommendation statement on Schedule 14D-9 carefully and to obtain those materials from the SEC or company websites. The filing includes customary forward-looking disclaimers and identifies social media posts made on March 31, 2026 as an exhibit.
Biogen’s subsidiary announced pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals under an Agreement and Plan of Merger dated March 31, 2026. The communication states the tender offer has not yet commenced and that formal offer materials will be filed on Schedule TO when the offer begins. It directs Apellis securityholders to read the forthcoming offer documents and the solicitation/recommendation statement on Schedule 14D-9 carefully and to obtain those materials from the SEC or company websites. The filing includes customary forward-looking disclaimers and identifies social media posts made on March 31, 2026 as an exhibit.
BIOGEN INC. Chief Accounting Officer Sean Godbout exercised 181 restricted stock units into 181 shares of common stock on April 1, 2026. The RSUs, granted on April 1, 2025, vest in three equal yearly installments, and this transaction reflects one vesting event.
To cover tax obligations, 54 shares of common stock were withheld at a price of $183.78 per share, leaving a net increase of 127 shares. Following these compensation-related transactions, Godbout directly holds about 1,341.6667 shares of Biogen common stock, indicating a routine equity vesting and tax-withholding pattern rather than open-market trading.
Biogen Inc. is buying Apellis Pharmaceuticals through a cash tender offer plus contingent value rights to expand its immunology and rare disease portfolio. Biogen will offer $41.00 in cash per Apellis share, valuing the upfront deal at approximately $5.6 billion.
Apellis stockholders will also receive one non‑transferable contingent value right per share, with potential additional cash payments of up to $4.00 per share tied to future global net sales milestones for SYFOVRE. The boards of both companies unanimously approved the merger, which uses a tender offer followed by a Section 251(h) Delaware merger and includes standard regulatory and minimum tender conditions.
Biogen Inc. — The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting zero shares of Biogen common stock and 0% beneficial ownership following an internal realignment.
The filing states certain Vanguard subsidiaries will report holdings separately under SEC Release No. 34-39538, effective after the January 12, 2026 realignment. The report is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Biogen Inc. reported that its Chief Legal Officer, Susan H. Alexander, will leave the company effective at the end of May 2026. The company has started a search for her successor to lead its legal function. Other aspects of Biogen’s operations are not discussed in this report.
Viehbacher Christopher reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that President and CEO Christopher Viehbacher received a grant of 38,015 restricted stock units on February 13, 2026. These units are a form of equity compensation and were awarded at a stated price of $0.00 per unit.
The restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the grant date of February 13, 2026. This means the award is structured to vest over three years, aligning the CEO’s compensation with longer-term company performance.
Singhal Priya reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that Priya Singhal, Head of Development, received a grant of 10,560 restricted stock units. These RSUs were awarded at no cash cost per unit as part of equity compensation. According to the disclosure, the units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date.